WO1990002188A1 - SUBSTITUTION PHAGE VECTOR μSK15 FOR CONSTRUCTION OF kDNA STRUCTURE GENE LIBRARIES - Google Patents
SUBSTITUTION PHAGE VECTOR μSK15 FOR CONSTRUCTION OF kDNA STRUCTURE GENE LIBRARIES Download PDFInfo
- Publication number
- WO1990002188A1 WO1990002188A1 PCT/SU1989/000230 SU8900230W WO9002188A1 WO 1990002188 A1 WO1990002188 A1 WO 1990002188A1 SU 8900230 W SU8900230 W SU 8900230W WO 9002188 A1 WO9002188 A1 WO 9002188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thousand
- phage
- size
- nuclei
- fragment
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 41
- 239000013598 vector Substances 0.000 title claims abstract description 30
- 238000010276 construction Methods 0.000 title abstract description 6
- 238000006467 substitution reaction Methods 0.000 title abstract description 3
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 229930027917 kanamycin Natural products 0.000 claims abstract description 5
- 229960000318 kanamycin Drugs 0.000 claims abstract description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims abstract description 5
- 229930182823 kanamycin A Natural products 0.000 claims abstract description 5
- 244000005700 microbiome Species 0.000 claims abstract description 4
- 238000011160 research Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 33
- 230000008569 process Effects 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 claims description 2
- 240000003023 Cosmos bipinnatus Species 0.000 claims description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 abstract description 3
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000702189 Escherichia virus Mu Species 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 101150085823 hsdR gene Proteins 0.000 abstract 1
- 108091008146 restriction endonucleases Proteins 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 229920001817 Agar Polymers 0.000 description 16
- 239000008272 agar Substances 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 229960000723 ampicillin Drugs 0.000 description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 13
- 239000002245 particle Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 4
- 241000555745 Sciuridae Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000011245 gel electrolyte Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002706 hydrostatic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012248 genetic selection Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 229910001234 light alloy Inorganic materials 0.000 description 2
- 230000001320 lysogenic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- KGKSTPKEAQNJJD-UHFFFAOYSA-N 1-bromo-3-methylpent-1-yn-3-ol Chemical compound CCC(C)(O)C#CBr KGKSTPKEAQNJJD-UHFFFAOYSA-N 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000004836 Glue Stick Substances 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000571 excretory cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011551 heat transfer agent Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
Definitions
- the project provides the ability to consume libraries of CDD genes using a large number of tests
- ⁇ 392 ⁇ ', ⁇ z ⁇ ⁇ 514 (r ⁇ , t ⁇ ) zi ⁇ 44, zi ⁇ ⁇ 58, 30 ⁇ as ⁇ ⁇ ( ⁇ as I ⁇ ) 6 ⁇ a1 ⁇ 2, e a1 ⁇ 22, those "L ⁇ , 1; g ⁇ 55 0 . ⁇ .
- the claimed vector allows you to receive libraries of industrial genes for the use of industrial and electronic recordings, which is a significant gain of interest in the study. This is the only
- the claimed vector allows, using biochemical and genetic selection, effective
- the inventive vector allows the possibility to carry out the expressions of CDD and the translation of M in the cells ⁇ . a mixture that carries a mutation of zi ⁇ C and / or zi ⁇ &, zi ⁇ D, zi ⁇ ⁇ . (" ⁇ réelle"). With this option, you can save libraries as well as traditional methods, as well as modifiable methods
- the claimed vector makes it easy to amplify the propagating gene using the Dreambook.
- the inventive part I-3' ⁇ 5 allows you to easily get rid of the “shoulders” of the phage L and transfer the insert to the plasmid form, and if the carcass is infected.
- SOSHE soderu- protects the plate
- the phobom-assistant of the UZ is located in the proteins of the phage OZ and is transferred to the single unit
- FIG. 2 illustrates the reduction of the 5–8 band
- Fig. 3 depicts the direct compression of the vector ⁇ ⁇ from phasmid ⁇ 5 ⁇
- Fig. 4 depicts the end of the phasing of the ages 15 at 5-5
- Fig. 5 depicts the scheme of copying the library of genes KDV in L 5–5 using the use of KAT ⁇
- Fig. 6 depicts the general design of a CD library in LP5 using the partial access of 20 20 kix cards
- Fig. 7 depicts the design of the KD ⁇ library in _D 5 comparativelyatter5 with the use of special links.
- BEST MODE FOR CARRYING OUT THE INVENTION The claimed phrased version L 5 ⁇ 5 is constituted on the 25th of the following scheme. Initially, they carry out the formation of the vector 5–8 (Figs. A, b and 2).
- I remove and clean the elec- tric element in the light-melting unit with the size of 1.86 thousand.
- the C79 promotes the production of waste and removes the constituent that contains the co-participation.
- ⁇ 5 ⁇ 2 is hydrolyzed and in conjunction with the group containing -
- Partition 5–6 hydrates the distant component, which allows for the loss of other components in the process
- 35 shtamgl Z. 109 which are sown on a medium containing • ampicillin, X- ⁇ , ⁇ .
- a medium containing • ampicillin, X- ⁇ , ⁇ Of the small species, in particular, with amcycillin, cells and excretory cells are dysfunctional.
- ⁇ For industrial purposes, ⁇ certify ⁇ , ⁇ - ⁇ , ⁇ ⁇ , ⁇ Vietnamese I, - 8 - in ⁇ ⁇ , ⁇ réelle ⁇ and analyze ⁇ . From the analysis of the identified data, a partition of 5–8 is distinguished, which is a quick hydrostatic access to the simplest section of the ISS and allows for the participation of the Russian Federation in the event of a permanent infection.
- the phasmids secrete the lobe from ⁇ 2 ⁇ .
- the loss of zone 2 is due to the loss of distance of 2 without participation in the recognition of social and social problems outside of the public domain. Then, the reduction of the recognition site of the disease is recognized in section 5-2.
- the phasing factor is 5 ⁇ 2 ⁇
- the league is introduced into the radial cage. sostokh d. 109, and disperse on agar with ampsitshinom. With a large size of prints on nitrous cellulose filters and converts hybridsing with the machine, it is possible to receive a good result. Battery from the cell
- I receive a flatbed ⁇ 4 ⁇ - ⁇ .
- the ⁇ 4 ⁇ plasma torch is used to stabilize the test and remove the reactant by heating 15 cables at 65 ° ⁇ . Then D phage I also expand and ⁇ agment
- the 10th case (Fig. 4), called ⁇ -- ⁇ , is used in the next stage, at the completion of the processing of ⁇ 5 ⁇ 5.
- ⁇ -- ⁇ For the plasti ⁇ 4 ⁇ - ⁇ , they hydrolyze the products of Soson and ⁇ a ⁇ and the reaction restores by heating 15 cables at 65 ° ⁇ . D ⁇ promotes cultivation
- the claimed phrasal vector L 5 ⁇ 5 may be used for the purpose of obtaining libraries for the permanent method with the use of the site - the site.
- Such and its recombinants may be converted to a club and other places.
- the integral axial separation of the phage on the mains plugs, the resis- tant to replicate the phage L (for example, ⁇ , ⁇ . ⁇ . ⁇ ) is inactive for 5-10 am-
- the percentage of recombinants in the library, obtained in L 5–5, is easy to target at random by re-injecting plaques on a gaz ⁇ 359 or using a colored gas
- the proposed dual lawn technology allows for the delivery of these disadvantages.
- the analyzed phages are incubated with the cells of the ⁇ .social strain ⁇ 392 and, after the recovery of the 0.6 ⁇ -th agaris, is sown in the cups of the Petri.
- this lawn is sown on lawn; the cage 0359 also - 16 - in the 0.6 ⁇ -th b-agar.
- recombinant phages of the dagota produce useful plaques, while non-recombinant phages are muddy, which is easily visualized.
- the claimed phrase vector is an unqualified replacement vector, which can be used for the purpose of downloading the library.
- the claimed vector implies:
- s ⁇ de ⁇ z haschem 50 m ⁇ ⁇ is- ⁇ S ⁇ ( ⁇ 7,5), 10 m ⁇ m ⁇ 2, 10 m ⁇ tsi ⁇ i ⁇ ei ⁇ a 3 m ⁇ atsen ⁇ zin ⁇ i ⁇ s ⁇ a ⁇ a 25 etsinits a ⁇ ivn ⁇ s ⁇ i D ⁇ ligase ⁇ aga ⁇ 4 m ⁇ g and 50 / ml summa ⁇ n ⁇ y D ⁇ .
- the league was won into
- the design which is conveniently flashed, is a quick-turnable quick-disconnect switch (fig. ⁇ ), and the above-mentioned ciphery wave is used for the most complete. With the aim of decreasing the size of 5, the burner will hydrate the rest of the product and at the same time (for 5 activity units), and
- the event is an ongoing event, an electrical process from a fusible plant after an electric power plant.
- 2 xi D ⁇ 5 ⁇ 2 ⁇ a ⁇ zhe gits ⁇ lizuyu ⁇ v ⁇ P and e ⁇ ⁇ e ⁇ a ⁇ a ⁇ ligi ⁇ uyu ⁇ with ⁇ agmen ⁇ m
- s ⁇ tse ⁇ z haschim s ⁇ z-uchas ⁇ in bu ⁇ e ⁇ e
- s ⁇ tse ⁇ z haschem 50 m ⁇ ⁇ is- ⁇ S ⁇ ( ⁇ 7,5), 10 m ⁇ ⁇ s ⁇ 2, Yu m ⁇ tsi ⁇ i ⁇ ei ⁇ a 3 m ⁇ atsen ⁇ zin ⁇ i ⁇ s ⁇ a ⁇ a ,
- na ⁇ dyascheg ⁇ sya is ⁇ lilin- ⁇ e ⁇ a, ⁇ agmen ⁇ m ⁇ len ⁇ va in ⁇ isu ⁇ s ⁇ vii ⁇ and ⁇ .E ⁇ ⁇ e ⁇ a ⁇ a ⁇ ⁇ b ⁇ aba ⁇ yvago ⁇ D ⁇ ligaz ⁇ y ⁇ aga ⁇ 4 (5 units a ⁇ iv- n ⁇ s ⁇ i) in 50 m ⁇ l ⁇ as ⁇ v ⁇ a, s ⁇ de ⁇ zhascheg ⁇ 50 m ⁇ ⁇ is- ⁇
- the phase-out factor combines the plague component ⁇ RB322 with the onset of the onset of replication and the gene for susceptibility to arterial hypertrophy, due to the
- 25 bacteria are produced on the chaffs of Petri with 2 $ agar, containing 25 g / ml agglicycillin, 0.1 G ⁇ and 0.1 $ X-a ⁇ .
- ⁇ - ⁇ This section, called ⁇ - ⁇ , is used for processing phage-vectors _ /? ⁇ 7 (fig. ⁇ ).
- 0.5 mcg for use in patients with disruption of ⁇ and the enzyme inactivate by ingestion.
- 3 mcg ⁇ ⁇ ⁇ 5 ⁇ 9 hydrolyzes the process of gas and food processing and inactivates the components by heating and purifying them from 20 relays-free for 600
- the mixture is mixed (weight ratio of two vectors and a genus of 2: 1) and the ligament is mixed with a total concentration of 250 mg / ml.
- 25 I • 10 mcg of the league DU are installed in the proteins of the phage ⁇ ⁇ - ⁇ réelle and 1/500 of the obtained phage particles are spread on the lawn Albany.
- p. 359 is just not out of the ordinary, so in general, recombinant phages are over 95. From 6 and 30 randomly collected plaques from the lawn ⁇ 392 in 10 ml of b - mediums from ⁇ 392 phages were grown and removed from them.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19893990972 DE3990972T1 (de) | 1989-08-29 | 1989-08-29 | Phagen-vektor der substitution (lambda)sk15 zum konstruiereen von bibliotheken der sturkturgene kdns |
GB9009525A GB2230012A (en) | 1988-08-31 | 1990-04-27 | Substitution phage vector lambda sk15 for construction of kdna gene libraries |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU884478259A SU1650699A1 (ru) | 1988-08-31 | 1988-08-31 | Фаговый вектор замещени @ К15 дл конструировани библиотек структурных генов к ДНК |
SU4478259/31 | 1988-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990002188A1 true WO1990002188A1 (en) | 1990-03-08 |
Family
ID=21397371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SU1989/000230 WO1990002188A1 (en) | 1988-08-31 | 1989-08-29 | SUBSTITUTION PHAGE VECTOR μSK15 FOR CONSTRUCTION OF kDNA STRUCTURE GENE LIBRARIES |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPH03505402A (enrdf_load_stackoverflow) |
DE (1) | DE3990972C2 (enrdf_load_stackoverflow) |
GB (1) | GB2230012A (enrdf_load_stackoverflow) |
SE (1) | SE465577B (enrdf_load_stackoverflow) |
SU (1) | SU1650699A1 (enrdf_load_stackoverflow) |
WO (1) | WO1990002188A1 (enrdf_load_stackoverflow) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU694269B2 (en) * | 1994-09-22 | 1998-07-16 | Merck Sharp & Dohme Corp. | Dna encoding human papillomavirus type 6a |
-
1988
- 1988-08-31 SU SU884478259A patent/SU1650699A1/ru active
-
1989
- 1989-08-29 WO PCT/SU1989/000230 patent/WO1990002188A1/ru active Application Filing
- 1989-08-29 DE DE19893990972 patent/DE3990972C2/de not_active Expired - Lifetime
- 1989-08-29 JP JP1509793A patent/JPH03505402A/ja active Pending
-
1990
- 1990-04-27 GB GB9009525A patent/GB2230012A/en not_active Withdrawn
- 1990-04-30 SE SE9001560A patent/SE465577B/sv not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
"DNA Cloning", Vol. II, Pod Redaktsiei D.M. GLOVER, 1985, IRL PRESS, (Oxford), pages 49-78. * |
BIOCHEMISTRY, Vol. 26, No. 6, 1987, (American Chemical Society), JANG H. HAN et al., "Isolation of Full-Length Putative Rat Lysophospholipase cDNA Using Improved Methods for mRNA Isolation and cDNA Cloning", pages 1617-1624. * |
NUCLEIC ACIDS RESARCH, Vol. 15, No. 15, 1987, (IRL Press Limited, Oxford, GB), JANG H. HAN et al., "Lambdagt22, an Improvedlambda Vector for the Directional Cloning of Full-Length cDNA", page 6304. * |
Also Published As
Publication number | Publication date |
---|---|
GB2230012A (en) | 1990-10-10 |
JPH03505402A (ja) | 1991-11-28 |
GB9009525D0 (en) | 1990-07-25 |
DE3990972C2 (enrdf_load_stackoverflow) | 1992-12-24 |
SE9001560D0 (sv) | 1990-04-30 |
SE9001560L (sv) | 1990-04-30 |
SE465577B (sv) | 1991-09-30 |
SU1650699A1 (ru) | 1991-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Species divergence in gut-restricted bacteria of social bees | |
Klenk et al. | Alligators as West Nile virus amplifiers | |
Dean et al. | Proteomics and comparative genomic investigations reveal heterogeneity in evolutionary rate of male reproductive proteins in mice (Mus domesticus) | |
HU230679B1 (en) | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions | |
Gerrick et al. | Metabolic diversity in commensal protists regulates intestinal immunity and trans-kingdom competition | |
Aldridge | The thread of life: the story of genes and genetic engineering | |
Fuyama | Species-specificity of paragonial substances as an isolating mechanism in Drosophila | |
Latham et al. | Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints | |
Enríquez | Genome editing and the jurisprudence of scientific empiricism | |
Kochva et al. | The special pattern of the venom gland in Atractaspis and its bearing on the taxonomic status of the genus | |
Yang et al. | Extracellular DNA in blood products and its potential effects on transfusion | |
Tortosa et al. | Chikungunya‐Wolbachia interplay in Aedes albopictus | |
Wishart et al. | Isolation of mouse neutrophils | |
Panno | Animal cloning: the science of nuclear transfer | |
Cao | CRISPR-Cas9 genome editing in Steinernema entomopathogenic nematodes | |
Forks | Brown recluse spider bites | |
Martins et al. | Protein deficiency alters CX 3 CL 1 and endothelin‐1 in experimental Trypanosoma cruzi‐induced cardiomyopathy | |
Serrano et al. | Paleogenomics of the prehistory of Europe: human migrations, domestication and disease | |
WO1990002188A1 (en) | SUBSTITUTION PHAGE VECTOR μSK15 FOR CONSTRUCTION OF kDNA STRUCTURE GENE LIBRARIES | |
Fu et al. | Prdm16-dependent antigen-presenting cells induce tolerance to intestinal antigens | |
Edelson | Francis Crick and James Watson: And the building blocks of life | |
Melendez | Future perspectives on veterinary hemoparasite research in the tropics at the start of this century | |
Rosenfeld et al. | Transfer factor: a subcellular component that transmits information for specific immune responses | |
Ratnoff | A war with the molecules: Louis Pillemer and the history of properdin | |
Wapner | The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CH DE GB JP KR SE US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 90015603 Country of ref document: SE |
|
WWP | Wipo information: published in national office |
Ref document number: 90015603 Country of ref document: SE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
RET | De translation (de og part 6b) |
Ref document number: 3990972 Country of ref document: DE Date of ref document: 19901122 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3990972 Country of ref document: DE |